Concepedia

Author

Akshata R. Udyavar

Vanderbilt UniversityORCID

Also Known As

A R Udyavar, A. Udyavar, A.R. Udyavar, Akshata R Udyavar, Akshata R. Udyavar, Akshata Ramrao Udyavar, Akshata Udyavar

66

Publications

649

Citations

11

H-Index

24

Concepts

All Affiliations

Vanderbilt UniversityPulse Biosciences (United States)Gene Therapy Laboratory
AR

About

Akshata R. Udyavar is an author at Vanderbilt University specializing in medicine, radiation oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

112

2

Cell Biology

3

3

94

3

Health Sciences

1

1

23

4

Immunology

1

1

26

5

Pathology

1

1

26

Akshata R. Udyavar

×

12

Publications

602

Citations

11

H-Index

YearCitations

Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer

Mélanie Desbois, Akshata R. Udyavar, Lisa Ryner,

Nature Communications

2020

192

Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity

Akshata R. Udyavar, David J. Wooten, Megan Hoeksema,

Cancer Research

2016

107

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer

Akshata R. Udyavar, Megan D. Hoeksema, Jonathan E. Clark,

BMC Systems Biology

2013

84

DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway

Sebahat Ocak, Hironobu Yamashita, Akshata R. Udyavar,

Oncogene

2010

45

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

Dana Piovesan, Joanne B.L. Tan, Annette Becker,

Molecular Cancer Therapeutics

2022

37

Subtle Affinity-Enhancing Mutations in a Myelin Oligodendrocyte Glycoprotein-Specific TCR Alter Specificity and Generate New Self-Reactivity

Akshata R. Udyavar, Rajshekhar Alli, Phuong Nguyen,

The Journal of Immunology

2009

26

ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).

Gulam A. Manji, Zev A. Wainberg, Kartik Krishnan,

Journal of Clinical Oncology

2021

26

Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional state

Wen Yan, Chi‐Yeh Chung, Tao Xie,

Molecular Oncology

2021

23

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers

Timothy R. Wilson, Akshata R. Udyavar, Ching‐Wei Chang,

Molecular Cancer Research

2018

20

Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

John D. Powderly, Alexander I. Spira, Rocío Gutiérrez,

Annals of Oncology

2019

18

Page 1